Thyrocare Technologies IPO Review
Mumbai based, Thyrocare Technologies IPO would open for subscription on 27thApril, 2016. Thyrocare Technologies Ltd has Pan India diagnostic chains. The company revenues grew at 23% CAGR in last 5 years. The company has made over 25% profits in the last couple of years. What are the positive factors in a Thyrocare Technologies IPO? What are the hidden factors about this IPO? Should you invest in this Thyrocare IPO or not? In this article, I would provide Thyrocare IPO Reviews
About Thyrocare Technologies Limited
Thyrocare Technologies Ltd Is one of the leading pan-India diagnostic chains and conduct an array of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases. As of February 29,2016, they offered 198 tests and 59 profiles of tests to detect a number of disorders, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility and various infectious diseases. Company profiles of tests include 16 profiles of tests administered under our“Aarogyam” brand, which offers patients a suite of wellness and preventive health care tests.
Also Read: Top Stock Brokers offering 3-in-1 demat account
Issue details of Thyrocare Technologies IPO
- IPO opens: 27-April-2016
- IPO closes: 29-April-2016
- Face Value: Rs 10 per share
- Issue price band: Rs 420 to Rs 446 per share
- Issue size: Rs 451 Crores
- Market lot:33 shares and in multiples of 33 shares therein
- Minimum investment: Rs 14,718 on lower price band
- Lead Managers: JM Financial institution, Edelweiss Capital and ICICI Securities
- Listing: BSE / NSE
- Download Thyrocare Technologies IPO Prospectus at this link
Purpose of Thyrocare Technologies IPO
1. Achieve the benefits of listing the Equity Shares on the BSE and the NSE and
2. Carry out the sale of up to 10,744,708 Equity Shares by the Selling Shareholders. The company would not receive any proceeds fro this OFS (Offer for sale).
3. General corporate purpose.
Company Financials (reinstated-standalone)
- The company generated revenue of Rs 81.2 Crores for the year ended Mar-11 and Rs 187.04 Crores for the year ended Mar-15. For 9 months ended Dec-15, it generated revenue of Rs 174.55 Crores.
- The company posted a profit of Rs 24.82 Crores for the year ended Mar-11 and profit of Rs 48.45 Crores for the year ended Mar-2015. For 9 months ended Dec-15, it generated a profit of Rs 43.58 Crores.
- Its restated EPS for FY 2015 is Rs 9.79and last 3 years average EPS Rs 9.9.
Reasons to invest Thyrocare Technologies IPO
- Revenues have grown from Rs 81.2 Crores FY11 to Rs 187.04 Crores in FY15 indicating a strong revenue growth of over 23% CAGR.
- Generated good margins of 25% to 29% in last 2 years and 9 months.
Also Read: How to boost returns from stock market investments?
Reasons not to invest in a Thyrocare Technologies IPO
- There are various proceedings pending against the Company and its Directors, Subsidiary, Promoters and certain Group Companies, which, if determined against them, may have an adverse effect on its business.
- The company operates in a highly-competitive and fragmented industry, and its business, financial condition and results of operations may be adversely affected if we are not able to compete effectively.
- Company business depends on its reputation and customer perception of its brand, and any negative publicity or other harm to its brand may materially and adversely affect its business, financial condition and results of operations. Further, any actions taken by its authorized service providers may harm its business and brand.
- Company pathology testing services are performed at the CPL located in Navi Mumbai and at the RPLs located in New Delhi, Coimbatore, Hyderabad, Kolkata and Bhopal. Any disruption in the operations of any of its laboratories could reduce or restrict sales and materially and adversely affect its business, financial condition, cash flows and results of operations.
- Company business is dependent on particular tests for a large majority of its revenue, and any disruption to such tests could materially and adversely affect its business, financial condition and results of operations.
- The company depends substantially on its hub-and-spoke business model complemented by the RPLs. Any delay or interruption in the transportation of samples to the CPL or the RPLs could adversely impact the effectiveness of its business model.
- Other risk factors (Internal and external) can be viewed in the draft prospectus from Page no. 15 onwards.
Recommendation / Investment strategy – Thyrocare Technologies IPO
- On the upper price band of Rs 446 and on FY15 EPS of Rs 9.79, P/E ratio works out to 45.5x. Similarly, on last 3 years EPS of Rs 9.9, P/E Ratio works out to be 45x. Means company is asking issue price forOn the upper p
- P/E ratio between 45x to 45.5x.
- Its competitors, Dr. Lal Pathlab shares are trading at a P/E ratio of 87x. There are no other listed peers. Hence, difficult to determine with one peer comparison that whether the issue price is priced over priced or under priced.
- Company revenues grown at 23% CAGR in last 5 years. It is generating good margins in the last 5 years. However, margins are on the decline side in last 2 yrs 9 months compared to earlier periods. Issue price looks on higher side. While financial performance looks good, one should re-think whether to buy at current level or should wait for some correction once it gets listed. Personally, I would wait for some time before buying such stocks at such high price. We have seen many IPO’s earlier, which has come with high issue price, but now available at discounted price i.e. below issue price.
Disclaimer: I do not have an interest in investing in this IPO. The idea of giving positive and negative factors to investors in this article is to create awareness and education about this IPO. One should NOT constitute this as investment advice to buy or not to buy. Please consult your investment advisor before you invest in such high risk investment options.
If you enjoyed this article, share it with your friends and colleagues through Facebook and Twitter.
Suresh
Thyrocare Technologies IPO Review
- Kosamattam Finance NCD – Nov-2024 Issue – Details and Review - November 24, 2024
- Best Large Cap Mutual Funds to Invest in 2025 - November 23, 2024
- How to Balance Risk and Reward in Your Investment Portfolio - November 19, 2024
You are right…its performance is average as of now
Feeling annoyed….. I have not got any allotment of Thyrocare BSE confirms, though I subscribed it on the very first day.
Can you make IPO a category on your blog so that it would be easy for us to navigate to it. I actually frequent the blog for the IPO Analysis you put up here. Its very informative.
will do that deepak
Suresh Sir, I have learnt that Thyrocare is only OFS on the other hand it has been subscribed 50% on the very first day which is a good sign. Now I am confused what to do. Shall I give it a try ? Please help.
can you please give RoA % , RONW , R O E ( at price ) , ROCE ,
return on capital , return on asset , RETURN ON NET WORTH ,
LAST 3 YEARS . . or last five year ?
if possible please provide R o A , RoE , R o C E etc.
generally , i do not invest at 25x P E ratio . .
this is much higher than 25 x , P/E . .
but depends on other factors also , 2 5 x or 100x .
Good Analysis. Thanks
Thanks Mr Suresh
Very Good analysis.. My doubt is cleared.. Keep it up and once again thanks for your brief comments about the IPO
I am new to investing in shares. I am planning to invest some amount in shares. Would like to know from you which company shares should I pick?
Mr. Suresh I appreciate your honesty for reviewing any IPO and giving information profitable to investors trusted in you.
Thank you and keep working same way.
Thank you Saurabh, keep recommending my blog to your friends
Thanks Suresh..Another great analysis…I read your every IPO analysis before taking a decision about the investment in any IPO.Keep up the good work.
Indias wrost company thyrocare if any new brand comes entire company people are ready to shift the profits are only from the un necessory debits recovered from their franchise centres and pay the salaries to their staff if franchise centres are going to boycott total company smash in couple of months all franchises are move to another brand which gives low price then thyrocare
Thank you. My doubt got cleared after reading this article.
Hi Suresh, I am a novice to stocks investment. What is the purpose of providing a range for the issue price (eg., Rs. 420 to Rs. 446 per share)? If I bid for one lot of shares at the lowest price range (Rs. 420), will my likelihood of allotment reduce compared to bidding at the highest price range (Rs. 446). Should I always bid at the highest price range?
It will be helpful if you can provide some info on this. Thanks.
It all depends on how much the IPO is subscribed. If the IPO is oversubscribed then there is a very chance that you will get it since your bid will be the smallest(not total amount but the bid price).
If you are really interested in buying this IPO, then you can do one of the 2.
1. submit 3 bids(as most of the broker allow) for lowest, mid and highest price
2. wait for the last day of IPO. By then you would know if the ipo is under or over subscribed. and based on that either submit the lower bid or highest bid.